Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
10.47
+0.06 (0.58%)
At close: Oct 15, 2026, 4:00 PM EDT
10.50
+0.03 (0.29%)
After-hours: Oct 15, 2026, 7:57 PM EDT
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $238.95M in the quarter ending June 30, 2026, with 19,582.54% growth. This brings the company's revenue in the last twelve months to $303.23M, up 1,495.93% year-over-year. In the year 2025, Vir Biotechnology had annual revenue of $68.56M, down -7.61%. That makes Vir Biotechnology the 14,440th largest company in the world by revenue and 2,615th in the United States.
Revenue (ttm)
$303.23M
Revenue Growth
+1,495.93%
P/S Ratio
5.84
Revenue / Employee
$826,232
Employees
367
Market Cap
1.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.56M | -5.65M | -7.61% |
| Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
| Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
| Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
| Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
| Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
| Dec 31, 2019 | 8.09M | -2.58M | -24.16% |
| Dec 31, 2018 | 10.67M | 7.96M | 293.94% |
| Dec 31, 2017 | 2.71M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Maravai LifeSciences Holdings | 208.78M |
| UroGen Pharma | 188.73M |
| Mesoblast | 120.25M |
| Xencor | 104.97M |
| Septerna | 98.88M |
| Agios Pharmaceuticals | 98.34M |
| Zymeworks | 37.13M |
VIR News
- 1 day ago - Vir Biotechnology enters collaboration, license agreement with Gilead - TheFly
- 1 day ago - Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors - Business Wire
- 7 days ago - Vir Biotechnology announces U.S. FDA granted FTD to VIR-5500 - TheFly
- 7 days ago - Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer - Business Wire
- 8 days ago - Vir Biotechnology price target raised to $22 from $20 at H.C. Wainwright - TheFly
- 8 days ago - Vir Biotechnology appoints Liu as Chief Medical Officer - TheFly
- 8 days ago - Vir Biotechnology Appoints David Liu as Chief Medical Officer - Business Wire
- 10 days ago - Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026 - Business Wire